Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2

Cell Mol Immunol. 2021 Jul;18(7):1829-1831. doi: 10.1038/s41423-021-00698-5. Epub 2021 May 31.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Angiotensin-Converting Enzyme 2 / biosynthesis*
  • Angiotensin-Converting Enzyme 2 / genetics
  • Antiviral Agents / pharmacology*
  • Binding Sites
  • COVID-19 / enzymology
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Enzyme Induction
  • HEK293 Cells
  • HeLa Cells
  • Humans
  • Interferon Type I / pharmacology*
  • Phosphorylation
  • Promoter Regions, Genetic
  • Receptors, Virus / biosynthesis*
  • Receptors, Virus / genetics
  • STAT1 Transcription Factor / antagonists & inhibitors*
  • STAT1 Transcription Factor / metabolism
  • Vidarabine / analogs & derivatives*
  • Vidarabine / pharmacology

Substances

  • Antiviral Agents
  • Interferon Type I
  • Receptors, Virus
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2
  • Vidarabine
  • fludarabine